References: Rousseau JF, Weber JM, Alhanti B, et al. Short-Term Safety and Effectiveness for Tenecteplase and Alteplase in Acute Ischemic Stroke. JAMA Netw Open. 2025;8(3):e250548. doi:10.1001 ...

HealthDay News — For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effectiveness and safety outcomes, according to a study published ...

At the current average wholesale cost of the smaller, commercially available alteplase vial (containing 50 mg), the average cost per milligram of alteplase is $27.50.

The 5-second intravenous bolus offers faster, simpler administration than Activase. HealthDay News — The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or ...

This is considerably faster than the standard of care, Activase ... Genentech, the manufacturer of TNKase, says a new 25-mg vial configuration will be available in the coming months.

TNKase is a faster, simpler stroke treatment, given as a single five-second IV bolus, unlike Activase’s 60-minute infusion. Genentech will soon launch a new 25 mg vial to support its AIS ...

TNKase is delivered as a single five-second intravenous bolus. This is considerably faster than the standard of care, Activase (alteplase), which is administered as an intravenous bolus followed by a ...

This is considerably faster than the standard of care, Activase ... Genentech, the manufacturer of TNKase, says a new 25-mg vial configuration will be available in the coming months.

TNKase is delivered as a single five-second intravenous (IV) bolus, a faster and simpler administration compared to the standard-of-care, Activase, which is administered as an IV bolus followed by a ...

About Activase ® (alteplase) Activase ® (alteplase) is indicated for treating patients with acute ischemic stroke (sudden stroke), which is caused by a blood clot in the brain’s blood vessels.